Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.41 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | MMP13 | P45452 | 3/20 | 0.38 |
| ▸ | ADAM17 | P78536 | 3/20 | 0.38 |
| ▸ | MMP2 | P08253 | 2/20 | 0.38 |
| ▸ | MMP14 | P50281 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21233488 | 0.91 | CYP4F2 (0.47) | PKMUSP2SMN1; SMN2CYP4F2CYP4A11 | |
| SCHEMBL21963889 | 0.87 | PKM (0.47) | PKMUSP2SMN1; SMN2CYP4F2CYP4A11 | |
| SCHEMBL16986998 | 0.87 | PKM (0.49) | PKMUSP2SMN1; SMN2CYP4F2CYP4A11 | |
| SCHEMBL2799709 | 0.86 | PKM (0.47) | PKMUSP2SMN1; SMN2CYP4F2CYP4A11 | |
| SCHEMBL22018261 | 0.85 | PKM (0.46) | PKMUSP2SMN1; SMN2CYP4F2CYP4A11 | |
| SCHEMBL4295685 | 0.84 | PKM (0.49) | PKMUSP2SMN1; SMN2CYP4F2CYP4A11 | |
| SCHEMBL3970403 | 0.84 | PKM (0.49) | PKMUSP2SMN1; SMN2CYP4F2CYP4A11 | |
| SCHEMBL27329418 | 0.84 | PKM (0.45) | PKMUSP2SMN1; SMN2CYP4F2CYP4A11 | |
| SCHEMBL29346987 | 0.83 | CYP4F2 (0.54) | PKMUSP2SMN1; SMN2CYP4F2CYP4A11 | |
| SCHEMBL4129353 | 0.83 | PKM (0.48) | PKMUSP2SMN1; SMN2CYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114369095-B | Aminopyrimidine compounds useful as SSAO inhibitors and methods for preparing the same | 伊莱利利公司 | 2025-03-14 | — | — | CN | disclosed |
| CN-114369095-A | Aminopyrimidine compounds useful as SSAO inhibitors and methods of making the same | 伊莱利利公司 | 2022-04-19 | — | — | CN | disclosed |
| CN-108778278-B | Aminopyrimidine compounds useful as SSAO inhibitors | 伊莱利利公司 | 2022-01-28 | — | — | CN | disclosed |
| EP-3582780-B1 | AMINO PYRIMIDINE COMPOUNDS USEFUL AS SSAO INHIBITORS | LILLY CO ELI (US) | 2021-10-13 | — | — | EP | disclosed |
| EP-3582780-B1 | AMINO PYRIMIDINE COMPOUNDS USEFUL AS SSAO INHIBITORS | LILLY CO ELI (US) | 2021-10-13 | — | — | EP | disclosed |
| US-10471060-B2 | Amino pyrimidine compounds useful as SSAO inhibitors | ELI LILLY AND COMPANY (US) | 2019-11-12 | — | — | US | disclosed |
| US-10471060-B2 | Amino pyrimidine compounds useful as SSAO inhibitors | ELI LILLY AND COMPANY (US) | 2019-11-12 | — | — | US | disclosed |
| US-20190275041-A1 | AMINO PYRIMIDINE COMPOUNDS USEFUL AS SSAO INHIBITORS | ELI LILLY AND COMPANY (US) | 2019-09-12 | — | — | US | disclosed |
| US-20190275041-A1 | AMINO PYRIMIDINE COMPOUNDS USEFUL AS SSAO INHIBITORS | ELI LILLY AND COMPANY (US) | 2019-09-12 | — | — | US | disclosed |
| US-10278970-B2 | Amino pyrimidine compounds useful as SSAO inhibitors | ELI LILLY AND COMPANY (US) | 2019-05-07 | — | — | US | disclosed |
| US-10278970-B2 | Amino pyrimidine compounds useful as SSAO inhibitors | ELI LILLY AND COMPANY (US) | 2019-05-07 | — | — | US | disclosed |
| US-20180296560-A1 | AMINO PYRIMIDINE COMPOUNDS USEFUL AS SSAO INHIBITORS | ELI LILLY AND COMPANY | 2018-10-18 | — | — | US | disclosed |
| WO-2018151985-A1 | AMINO PYRIMIDINE COMPOUNDS USEFUL AS SSAO INHIBITORS | ELI LILLY AND COMPANY (US) | 2018-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10278970-B2 | Amino pyrimidine compounds useful as SSAO inhibitors | DPYD, TYMP, NUDT1 | PKM 1269/4885USP2 4800/4885SMN1; SMN2 1089/4885 |
| US-20180296560-A1 | AMINO PYRIMIDINE COMPOUNDS USEFUL AS SSAO INHIBITORS | DPYD, TYMP, NUDT1 | PKM 1269/4885USP2 4800/4885SMN1; SMN2 1089/4885 |
| US-10471060-B2 | Amino pyrimidine compounds useful as SSAO inhibitors | DPYD, TYMP, NUDT1 | PKM 1269/4885USP2 4800/4885SMN1; SMN2 1089/4885 |
| US-20190275041-A1 | AMINO PYRIMIDINE COMPOUNDS USEFUL AS SSAO INHIBITORS | DPYD, TYMP, NUDT1 | PKM 1269/4885USP2 4800/4885SMN1; SMN2 1089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.